NICE recommends Opdivo to treat head and neck cancer.- BMS.

When the National Institute for Health and Care Excellence (NICE) first reviewed Opdivo (nivolumab), it found that the evidence for its effectiveness in treating head and neck cancer was uncertain. NICE invited BMS to submit a Cancer Drugs Fund (CDF) proposal to show how they would strengthen the evidence for the drug. This proposal was submitted and Opdivo will now be available for patients with head and neck cancer who have not responded to chemotherapy within 6 months, and the cancer has spread to other parts of the body.

Patients can now have access to the drug via the NHS whilst it is within the CDF. During this time, further data will be collected from how well patients do who access the drug through the CDF and from a clinical trial to help address uncertainties in the evidence.